Compare Neurocrine Biosciences Inc (NBIX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Under Armour Inc Class A — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Under Armour Inc Class A trades at $7.3 (market cap $3.07B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.7× Under Armour Inc Class A's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| NBIX | UAA | |
|---|---|---|
Market Cap | $17.40B | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $8.14 |
52-Week Low | $123.10 | $4.17 |
Enterprise Value | $16.49B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UAA) trades at $7.37, down 0.81% today, with mixed signals: technicals are bullish on moving averages but RSI suggests overbought conditions. Fundamentally, the company reported a net loss of $201.27M in 2025 with negative margins, though recent quarters showed earnings beats. Cash flow trends are volatile, with 2025 net cash outflow of $361.87M. News highlights include a new Dodge collaboration and upcoming Q1 2027 earnings on August 7, 2026.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth offers some offset. Analyst consensus is cautious with a $5.96 price target below current levels. Key risks include consumer spending softness and high debt. For investors, stabilization in earnings and cost control are critical for a turnaround, though near-term headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
